Results 151 to 160 of about 7,837 (201)
Clopidogrel-induced acquired haemophilia A in a post-TAVR patient: a case report and literature review. [PDF]
Eur Heart J Case RepZaman M +4 more
europepmc +1 more source
Neurosurgical management of intracerebral hemorrhage in anticoagulated patients: Outcomes and reversal strategies. [PDF]
Brain CircGrover V, Ding Y.
europepmc +1 more source
It is premature to use recombinant activated coagulation factor VIIa in intracerebral hemorrhage
Annals of Indian Academy of Neurology, 2007 Prasad Kameshwar
doaj
Transformative approaches in hemophilia management: from traditional therapies to prenatal stem cell treatment. [PDF]
Front Bioeng BiotechnolKao YT +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Safety profile of recombinant factor VIIa
Seminars in Hematology, 2004Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors. More recently, rFVIIa has also shown considerable success as a hemostatic agent in trauma and surgery patients without pre-existing coagulopathy ...
Dougald M Monroe, Maureane Hoffman
exaly +3 more sources
BioDrugs, 1999
Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. Indicators of activation of systemic coagulation of blood were unchanged and mean prothrombin times and ...
C J, Dunn, C M, Spencer
openaire +4 more sources
Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. Indicators of activation of systemic coagulation of blood were unchanged and mean prothrombin times and ...
C J, Dunn, C M, Spencer
openaire +4 more sources
Emergency Medicine, 2004
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire +2 more sources
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire +2 more sources